These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 20820028

  • 1. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS, Outterson K.
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [Abstract] [Full Text] [Related]

  • 2. Repairing the broken market for antibiotic innovation.
    Outterson K, Powers JH, Daniel GW, McClellan MB.
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [Abstract] [Full Text] [Related]

  • 3. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
    Hsu LY, Kwa AL, Lye DC, Chlebicki MP, Tan TY, Ling ML, Wong SY, Goh LG.
    Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
    [Abstract] [Full Text] [Related]

  • 4. Antibiotic research and development: business as usual?
    Harbarth S, Theuretzbacher U, Hackett J, DRIVE-AB consortium.
    J Antimicrob Chemother; 2015 Oct; 70(6):1604-7. PubMed ID: 25673635
    [Abstract] [Full Text] [Related]

  • 5. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM, Mossialos E.
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [Abstract] [Full Text] [Related]

  • 6. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
    Bergström R.
    Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
    [Abstract] [Full Text] [Related]

  • 7. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development.
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [Abstract] [Full Text] [Related]

  • 8. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B, Bartlett J, Wunderink R, Gilbert DN.
    Am J Respir Crit Care Med; 2015 Jan 15; 191(2):135-40. PubMed ID: 25590154
    [Abstract] [Full Text] [Related]

  • 9. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS, Outterson K.
    Yale J Health Policy Law Ethics; 2011 Jan 15; 11(1):101-67. PubMed ID: 21381513
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B, Miller LG, Kuo MN, Bradley J, Scheld WM, Edwards JE.
    Infection; 2007 Jun 15; 35(3):167-74. PubMed ID: 17565458
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH, Outterson K.
    Lancet Infect Dis; 2016 Apr 15; 16(4):500-5. PubMed ID: 27036356
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.
    Aiello AE, King NB, Foxman B.
    Am J Public Health; 2006 Nov 15; 96(11):1910-4. PubMed ID: 17018817
    [Abstract] [Full Text] [Related]

  • 17. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb 15; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 18. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J.
    BMJ; 2016 May 19; 353():i2863. PubMed ID: 27198868
    [No Abstract] [Full Text] [Related]

  • 19. Impact of antibiotic restrictions: the pharmaceutical perspective.
    Power E.
    Clin Microbiol Infect; 2006 Aug 19; 12 Suppl 5():25-34. PubMed ID: 16827822
    [Abstract] [Full Text] [Related]

  • 20. Innovation of novel antibiotics: an economic perspective.
    McKellar MR, Fendrick AM.
    Clin Infect Dis; 2014 Oct 15; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.